These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38680489)

  • 1. Development of a visual Adhesion/Invasion Inhibition Assay to assess the functionality of
    Batani G; Vezzani G; Lashchuk S; Allaoui A; Cardamone D; Raso MM; Boero E; Roscioli E; Ridelfi M; Gasperini G; Pizza M; Rossi O; Berlanda Scorza F; Micoli F; Rappuoli R; Sala C
    Front Immunol; 2024; 15():1374293. PubMed ID: 38680489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Do the Virulence Factors of
    Mattock E; Blocker AJ
    Front Cell Infect Microbiol; 2017; 7():64. PubMed ID: 28393050
    [No Abstract]   [Full Text] [Related]  

  • 3. Shigella interaction with intestinal epithelial cells determines the innate immune response in shigellosis.
    Fernandez MI; Sansonetti PJ
    Int J Med Microbiol; 2003 Apr; 293(1):55-67. PubMed ID: 12755366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 5. Shigella Diversity and Changing Landscape: Insights for the Twenty-First Century.
    Anderson M; Sansonetti PJ; Marteyn BS
    Front Cell Infect Microbiol; 2016; 6():45. PubMed ID: 27148494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
    Davis CL; Wahid R; Toapanta FR; Simon JK; Sztein MB
    PLoS One; 2018; 13(1):e0189571. PubMed ID: 29304144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.
    Chowers Y; Kirschner J; Keller N; Barshack I; Bar-Meir S; Ashkenazi S; Schneerson R; Robbins J; Passwell JH
    Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2396-401. PubMed ID: 17287349
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Schnupf P; Sansonetti PJ
    Microbiol Spectr; 2019 Mar; 7(2):. PubMed ID: 30953429
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multivalent Adhesion Molecule SSO1327 plays a key role in Shigella sonnei pathogenesis.
    Mahmoud RY; Stones DH; Li W; Emara M; El-Domany RA; Wang D; Wang Y; Krachler AM; Yu J
    Mol Microbiol; 2016 Feb; 99(4):658-73. PubMed ID: 26481305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics.
    Davis CL; Wahid R; Toapanta FR; Simon JK; Sztein MB; Levy D
    PLoS One; 2013; 8(4):e59465. PubMed ID: 23589755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp.
    Oaks EV; Picking WD; Picking WL
    Clin Diagn Lab Immunol; 1996 Mar; 3(2):242-5. PubMed ID: 8991646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Enteric α-Defensin 5 Promotes Shigella Infection by Enhancing Bacterial Adhesion and Invasion.
    Xu D; Liao C; Zhang B; Tolbert WD; He W; Dai Z; Zhang W; Yuan W; Pazgier M; Liu J; Yu J; Sansonetti PJ; Bevins CL; Shao Y; Lu W
    Immunity; 2018 Jun; 48(6):1233-1244.e6. PubMed ID: 29858013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune response to Shigella sonnei in U.S. Marines.
    Mikhail MM; Mansour MM; Oyofo BA; Malone JD
    Infect Immun; 1996 Sep; 64(9):3942-5. PubMed ID: 8751956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum enterotoxin-neutralizing antibody in human shigellosis.
    Keusch GT; Jacewicz M
    Nat New Biol; 1973 Jan; 241(105):31-2. PubMed ID: 4572837
    [No Abstract]   [Full Text] [Related]  

  • 18. Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?
    Phalipon A; Sansonetti PJ
    Immunol Cell Biol; 2007; 85(2):119-29. PubMed ID: 17213832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive properties of virulent Shigella strains].
    Borisova EB
    Mikrobiol Z; 2000; 62(1):64-72. PubMed ID: 11300086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH; Freier S; Shor R; Farzam N; Block C; Lison M; Shiff E; Ashkenazi S
    Pediatr Infect Dis J; 1995 Oct; 14(10):859-65. PubMed ID: 8584312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.